Telaprevir

Janessa Smith, Pharm.D. BCPS, Paul A. Pham, Pharm.D.

INDICATIONS

FDA

No longer available in the U.S.

  • In combination with peg-interferon and ribavirin, telaprevir indicated for the treatment of HCV (genotype1) patients with compensated liver disease, including cirrhosis, who are treatment-naïve OR who have been previously treated with interferon-based regimen, but had no response, partial response, or relapsed

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: October 11, 2026